New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
09:29 EDTVRX
theflyonthewall.com: Investors may be too bullish on Valeant Pharmaceutical, Barron's says
Investors may be too optimistic about the potential of Valeant Pharmaceutical's (VRX) epilepsy drug, retigabine, Barron's warns. Retigabine may not be able to compensate for reduced royalties from Valeant's top seller, an antiviral treatment called ribavirin, according to the publication. Meanwhile, Retigabine's side effects caused a large number of patients to withdraw from a clinical study of the drug, Barron's notes. Reference Link :theflyonthewall.com



News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2010
06:26 EDTVRX
theflyonthewall.com: Valeant Pharm initiated with a Buy at Jefferies

Subscribe for More Information
:theflyonthewall.com